4.8 Article

Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis

Journal

GASTROENTEROLOGY
Volume 159, Issue 4, Pages 1290-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2020.06.006

Keywords

Gastric Banding; Gastric Bypass; Roux-en-Y-Gastric-Bypass; Sleeve Gastrectomy

Funding

  1. French Ministry of Health (Programme Hospitalier de Recherche Clinique)
  2. Conseil Regional Nord-Pas de Calais (ARCIR Obesite et Alcool)
  3. Agence National de la Recherche (European Genomic Institute for Diabetes [EGID]) [ANR-10LABX-46]
  4. European commission (FEDER)
  5. Agence National de la Recherche (PreciNASH) [ANR-16-RHUS-0006]

Ask authors/readers for more resources

BACKGROUND AND AIMS: Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH. METHODS: We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of >= 1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years. RESULTS: At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less-weight loss (reduction in body mass index of 6.3 +/- 4.1 kg/m(2) in patients with persistent NASH vs reduction of 13.4 +/- 7.4 kg/m(2); P=.017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years (P=.17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years (P<.001). CONCLUSIONS: In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available